In vivo mice were injected with EL4-hCD20-Luc cells and then injected with 277.5 kBq of Pb212rituximabb after an interval of either 11, 20, or 30 days. Median overall survival was much better in the 11-day p.i. Group—105 days compared with 64 days for the most positive control sample.
The Renaissance of Radio Pharmaceuticals – A Commercial Perspective
Kathryn Hayashi, President and CEO, TRIUMF Innovations Dr. Mike Abrams, Biopharmaceutical Consultant
Presented by: Stephanie Durand-Panateix, PhD, University of Limoges, Limoges, France
Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada